Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer

ROS proto-oncogene 1 (ROS1) rearrangements occur in 0.9–2.6% of patients with non small cell lung cancer (NSCLC), conferring sensitivity to treatment with specific tyrosine-kinase inhibitors (TKI). Crizotinib, a first-generation TKI, was the first target-therapy approved for the first-line treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanzione, Brigida, Del Conte, Alessandro, Bertoli, Elisa, De Carlo, Elisa, Revelant, Alberto, Spina, Michele, Bearz, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380455/
https://www.ncbi.nlm.nih.gov/pubmed/37511255
http://dx.doi.org/10.3390/ijms241411495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380455/
https://www.ncbi.nlm.nih.gov/pubmed/37511255
http://dx.doi.org/10.3390/ijms241411495

Ejemplares similares